Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, offers short-term improvements in health-related quality of life and work productivity in people with narcolepsy, according to study results published in Sleep Medicine.
Narcolepsy has been linked to several significant effects on quality of life in people living with this disease. For example, the rate of job loss ranges from 37% to 52%, which is attributed to the deleterious effects on job performance as a result of the symptoms of narcolepsy. There is no cure for narcolepsy; treatments aim to ameliorate symptoms. Solriamfetol is approved for the use of improving wakefulness in adult patients.
Because few studies have evaluated the efficacy of treatment on functioning, QoL, and work productivity, researchers conducted a 12-week, randomized, double-blind, placebo-controlled, multicenter, 4-arm, parallel-group study to evaluate the safety and efficacy of solriamfetol for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. The primary outcome measures were changes in functional status related to sleepiness, HRQoL, and work productivity.